An objective method to assess the improvements of skin texture roughness after botulinum toxin type a treatment of crow's feet

Skin Res Technol. 2019 Jan;25(1):54-59. doi: 10.1111/srt.12595. Epub 2018 Jun 6.


Background: Photo-numeric scales could lack precision and objectivity on evaluating the improvements on wrinkles after a treatment with botulinum toxin type A. The authors suggest a new digital evaluation method to analyze its effectiveness.

Objectives: This study aims to investigate retrospectively the effect of intramuscular injection of botulinum toxin type A on skin texture in the lateral peri-orbital region with a new objective method.

Methods: Skin texture roughness (STR) in the lateral peri-orbital region is evaluated with a multi-directional light beam by light emitting diodes of different wavelengths (Antera 3D® ), before and after injections of 12 units of botulinum toxin type A. The wrinkles and lines deeper than 0.5 mm are filtered to measure accurately skin texture.

Results: We observed an improvement of STR in all cases treated with botulinum toxin type A. A significant decrease of STR was recorded as follows: 17.08% (P < .0001) at 4 weeks and 12.14% at 4 months (P = .001).

Conclusion: Botulinum toxin type A treatment of crow's feet was able to improve STR. The Antera® device and software are a valuable, objective, easy and reproducible method to assess the effects of the toxin.

Keywords: Antera 3D®; botulinum toxin; crow's feet; roughness; texture.

MeSH terms

  • Acetylcholine Release Inhibitors / administration & dosage*
  • Acetylcholine Release Inhibitors / pharmacology
  • Adult
  • Aged
  • Botulinum Toxins, Type A / administration & dosage*
  • Botulinum Toxins, Type A / pharmacology
  • Dermal Fillers / administration & dosage
  • Dermal Fillers / pharmacology
  • Female
  • Humans
  • Injections, Intramuscular
  • Middle Aged
  • Retrospective Studies
  • Skin / anatomy & histology*
  • Skin / drug effects
  • Skin Aging / drug effects*
  • Skin Aging / physiology
  • Software
  • Treatment Outcome


  • Acetylcholine Release Inhibitors
  • Dermal Fillers
  • Botulinum Toxins, Type A

Grant support